Back

ACE2 expression and localization are regulated by CFTR: implications beyond cystic fibrosis

Bezzerri, V.; Gentili, V.; Api, M.; Finotti, A.; Papi, C.; Tamanini, A.; Olioso, D.; Duca, M.; Tedesco, E.; Leo, S.; Borgatti, M.; Volpi, S.; Pinton, P.; Cabrini, G.; Gambari, R.; Blasi, F.; Lippi, G.; Rimessi, A.; Rizzo, R.; cipolli, m.

2021-11-22 cell biology
10.1101/2021.11.19.469220 bioRxiv
Show abstract

As an inherited disorder characterized by severe pulmonary disease, cystic fibrosis (CF) could be considered a comorbidity for coronavirus disease 2019 (COVID-19)1. Instead, CF seems to constitute an advantage in COVID-19 infection2-5. To clarify whether host factors expressed by the CF epithelia may influence COVID-19 progression, we investigated the expression of SARS-CoV-2 receptor and coreceptors in primary airway epithelial cells. We found that angiotensin converting enzyme 2 (ACE2) expression and localization are regulated by cystic fibrosis transmembrane conductance regulator (CFTR) channels. Consistently, our results indicate that dysfunctional CFTR channels alter susceptibility to SARS-CoV-2 infection, resulting in reduced viral infection in CF cells. Depending on the pattern of ACE2 expression, the SARS-CoV-2 spike (S) protein induced high levels of Interleukin (IL)-6 in healthy donor-derived primary airway epithelial cells but a very weak response in primary CF cells. Collectively, these data support the hypothesis that CF condition is unfavorable for SARS-CoV-2 infection.

Matching journals

The top 12 journals account for 50% of the predicted probability mass.

1
Scientific Reports
3102 papers in training set
Top 5%
10.4%
2
American Journal of Respiratory Cell and Molecular Biology
38 papers in training set
Top 0.1%
7.4%
3
American Journal of Physiology-Lung Cellular and Molecular Physiology
39 papers in training set
Top 0.1%
5.0%
4
Cellular and Molecular Life Sciences
84 papers in training set
Top 0.1%
5.0%
5
iScience
1063 papers in training set
Top 3%
4.4%
6
European Respiratory Journal
54 papers in training set
Top 0.5%
3.7%
7
Communications Biology
886 papers in training set
Top 2%
3.3%
8
Allergy
23 papers in training set
Top 0.2%
3.0%
9
Journal of Cystic Fibrosis
15 papers in training set
Top 0.1%
2.8%
10
eLife
5422 papers in training set
Top 31%
2.7%
11
Life Science Alliance
263 papers in training set
Top 0.1%
2.1%
12
JCI Insight
241 papers in training set
Top 2%
2.1%
50% of probability mass above
13
Nature Communications
4913 papers in training set
Top 48%
1.9%
14
Biochemical and Biophysical Research Communications
78 papers in training set
Top 0.4%
1.8%
15
EBioMedicine
39 papers in training set
Top 0.3%
1.7%
16
The American Journal of Pathology
31 papers in training set
Top 0.2%
1.7%
17
Cells
232 papers in training set
Top 3%
1.4%
18
The FASEB Journal
175 papers in training set
Top 1%
1.4%
19
Cell Discovery
54 papers in training set
Top 3%
1.4%
20
Clinical and Translational Medicine
30 papers in training set
Top 0.5%
1.3%
21
Hypertension
32 papers in training set
Top 0.6%
1.1%
22
Frontiers in Cell and Developmental Biology
218 papers in training set
Top 6%
1.1%
23
Journal of Biological Chemistry
641 papers in training set
Top 3%
1.1%
24
Investigative Opthalmology & Visual Science
37 papers in training set
Top 0.5%
1.0%
25
Nature Medicine
117 papers in training set
Top 4%
0.9%
26
Journal of Clinical Investigation
164 papers in training set
Top 6%
0.8%
27
International Journal of Molecular Sciences
453 papers in training set
Top 14%
0.8%
28
Molecular Therapy
71 papers in training set
Top 3%
0.8%
29
PLOS Genetics
756 papers in training set
Top 14%
0.8%
30
Frontiers in Pharmacology
100 papers in training set
Top 4%
0.8%